[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
[PDF][PDF] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small …
HA Jung, SY Woo, SH Lee, JS Ahn, MJ Ahn, K Park… - cdn.amegroups.cn
Background: Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell …
HA Jung, SY Woo, SH Lee… - Translational …, 2020 - mdanderson.elsevierpure.com
Background: Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational lung …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - tlcr.amegroups.org
Background: Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell …
HA Jung, SY Woo, SH Lee, JS Ahn, MJ Ahn… - Translational Lung …, 2020 - europepmc.org
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell …
HA Jung, SY Woo, SH Lee, JS Ahn… - TRANSLATIONAL …, 2020 - scholarworks.bwise.kr
Background: Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
[引用][C] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small …
HA Jung, SY Woo, SH Lee, JS Ahn, MJ Ahn… - … Lung Cancer Research, 2020 - cir.nii.ac.jp
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients
with epidermal growth factor receptor mutation-positive non-small cell lung cancer | CiNii …
with epidermal growth factor receptor mutation-positive non-small cell lung cancer | CiNii …
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - tlcr.amegroups.org
Data Sharing Statement Page 1 Data Sharing Statement Article Info Article Information: http://dx.doi.org/10.21037/tlcr-20-379
Item Question Authors’ Response (place “-” if not applicable) 1 Would you like to share data …
Item Question Authors’ Response (place “-” if not applicable) 1 Would you like to share data …